Research & Guides
Melanotan I and Afamelanotide: Read the Product Behind the FDA Label
Novembre 3, 2026
An FDA-approved medicine can share a research name with a catalog compound without making that catalog product FDA approved. Melanotan I and afamelanotide searches are a useful example of why the product behind the label matters.
This is a reading of existing US regulatory records, checked November 4, 2026. It is not a new approval announcement and does not describe the regulatory position in every country.
What the FDA record actually identifies
The FDA approval record names SCENESSE, with afamelanotide as its active ingredient, and gives an approval date of October 8, 2019. The cited prescribing information identifies a specific implant medicine for increasing pain-free light exposure in adults with a history of phototoxic reactions from erythropoietic protoporphyria, or EPP.
That is a defined disease-related indication. It should not be rewritten as a general cosmetic-tanning approval or approval of products sold under a related research name.
The label contains more than a molecule
A medicine’s label connects an active ingredient with a dosage form, a manufacturer-controlled product and an approved clinical context. Matching one name in that chain does not establish the rest. A research vial is not interchangeable with the labeled implant merely because a description connects both with afamelanotide.
The label also contains important safety information, including hypersensitivity warnings, pigmentation-related monitoring and the need to maintain light-protection measures. Those details belong with discussion of the approved medicine. They should not disappear behind the word “approved.” No administration instructions are provided here.
Why this distinction helps a buyer read information
Our view is that the most useful approval claim names the actual medicine and the exact indication. If a page only says “FDA approved” next to a molecule name, the reader still has several unanswered questions: which product, which formulation and for what purpose?
A facility registration, an ingredient listing or a supplier document answers a different question. None substitutes for an approval record tied to the product being discussed.
How this relates to the catalog
The MT-1 research-catalog entry is a separate laboratory-material listing. This article does not verify it as an equivalent of SCENESSE or as an approved medicine. For another product-specific example, our SS-31, elamipretide and Forzinity guide separates research terminology from the named approved product.
The opportunity is clearer communication: a precise approval statement gives readers something they can verify. Keeping the medicine, indication and research material distinct makes that statement more useful.
Sources
- FDA, SCENESSE prescribing information, 2024 revision
- FDA orphan-drug approval record for afamelanotide, approval October 8, 2019
Source review: November 4, 2026. The dated studies above are background research, not new announcements.